{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:50:30Z","timestamp":1791852630923,"version":"4.3.4"},"reference-count":27,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"abstract":"Abstract<\/jats:title>\n \n Background and Objectives<\/jats:title>\n Platelet concentrates (PC) are essential for haemostatic support in clinical care. The Welsh Blood Service (WBS) previously showed through data modelling that three\u2010buffy\u2010coat\u2010derived PC (3BC\u2010PC) could meet UK contingency and European Directorate for the Quality of Medicines & HealthCare (EDQM) Council of Europe specifications. This study aimed to validate the real\u2010world manufacture of 3BC\u2010PC, assessing quality and compliance against UK and European regulatory standards.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods<\/jats:title>\n \n Three\n ABO<\/jats:styled-content>\n \u2010compatible BCs were pooled with platelet additive solution\u2010E (\n PAS<\/jats:styled-content>\n \u2010E) and processed per standard\n WBS<\/jats:styled-content>\n protocols. Sixteen\n 3BC<\/jats:styled-content>\n \u2010\n PC<\/jats:styled-content>\n were manufactured and stored at 20\u201324\u00b0C with agitation for 7\u2009days. Samples were tested on Days 1, 2, 6 and 8 for platelet yield, recovery and specification compliance. Functional and quality assessments included platelet activation (\n CD62P<\/jats:styled-content>\n , Annexin V, soluble\n CD62P<\/jats:styled-content>\n ), biochemistry (\n pH<\/jats:styled-content>\n , glucose, lactate), light transmission aggregometry (adenosine diphosphate [\n ADP]<\/jats:styled-content>\n , thrombin receptor activator peptide\u20106 [\n TRAP<\/jats:styled-content>\n \u20106]) and thromboelastography (TEG) (R, K, \u03b1\u2010angle, maximum amplitude [\n MA]<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Mean platelet yield was 247\u2009\u00b1\u200926\u2009\u00d7\u200910\n 9<\/jats:sup>\n \/unit following Day 2 bacteriology sampling. All 3BC\u2010PC met UK contingency (\u2265150\u2009\u00d7\u200910\n 9<\/jats:sup>\n \/unit) and EDQM routine (\u2265200\u2009\u00d7\u200910\n 9<\/jats:sup>\n \/unit) specifications throughout storage, although UK routine compliance (\u2265240\u2009\u00d7\u200910\n 9<\/jats:sup>\n \/unit) declined to 62.5% following Day 2 bacteriology sampling. Biochemical, activation and functional changes reflected expected platelet storage lesions, while TEG showed preserved global haemostatic function.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Practical validation supports the feasibility of 3BC\u2010PC as a contingency component. Quality metrics aligned with UK and European specifications, suggesting operational and clinical viability. These findings bridge prior modelling with practical manufacture and support both UK contingency and routine European adoption while identifying future optimisation considerations for potential routine UK use.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/vox.70387","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:25:06Z","timestamp":1791851106000},"source":"Crossref","is-referenced-by-count":0,"title":["Three\u2010buffy\u2010coat platelet concentrates: Evaluation of a Welsh blood supply chain contingency strategy with wider opportunities for European practice"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5211-920X","authenticated-orcid":false,"given":"Michael","family":"Cahillane","sequence":"first","affiliation":[{"name":"Welsh Blood Service Pontyclun UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pearce","sequence":"additional","affiliation":[{"name":"Welsh Blood Service Pontyclun UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7010-6068","authenticated-orcid":false,"given":"Christine","family":"Saunders","sequence":"additional","affiliation":[{"name":"Welsh Blood Service Pontyclun UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-378X","authenticated-orcid":false,"given":"Chloe","family":"George","sequence":"additional","affiliation":[{"name":"Welsh Blood Service Pontyclun UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Hoffbrand's essential haematology","author":"Hoffbrand AV","year":"2024"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"Guidelines for the use of platelet transfusions","volume":"176","author":"Estcourt L","year":"2016","journal-title":"Br J Haematol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.moh.0000239703.40297.a5","article-title":"A critical comparison of platelet preparation methods","volume":"13","author":"Vassallo RR","year":"2006","journal-title":"Curr Opin Hematol"},{"key":"e_1_2_9_5_1","unstructured":"JPAC.Chapter 7.4.3: platelets pooled buffy coat derived in additive solution and plasma leucocyte depleted.2026. Guidelines for the blood transfusion and tissue transplantation services in the UK. London UK. Available from:https:\/\/www.transfusionguidelines.org. Last accessed 9 Mar 2026."},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/vox.70090","article-title":"Three buffy coat platelet concentrates: use of data modelling to make more with less","volume":"120","author":"Cahillane M","year":"2025","journal-title":"Vox Sang"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(20)30186-1","article-title":"Effects of the COVID\u201019 pandemic on supply and use of blood for transfusion","volume":"7","author":"Stanworth SJ","year":"2020","journal-title":"Lancet Haematol"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17474086.2023.2209716","article-title":"Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID\u201019","volume":"16","author":"Denakker TA","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"e_1_2_9_9_1","unstructured":"JPAC.Chapter A5.2: platelets apheresis leucocyte depleted at reduced dose as a contingency.2026.\u00a0Guidelines for the blood transfusion and tissue transplantation services in the UK. London UK. Available from:https:\/\/www.transfusionguidelines.org. Last accessed 9 Mar 2026."},{"key":"e_1_2_9_10_1","volume-title":"Guide to the preparation, use and quality assurance of blood components","author":"EDQM","year":"2025"},{"key":"e_1_2_9_11_1","unstructured":"JPAC.Chapter 8.3: evaluation of new platelet components for transfusion. 2022. Guidelines for the blood transfusion and tissue transplantation services in the UK. London UK. Available from:https:\/\/www.transfusionguidelines.org. Last accessed 9 Mar 2026."},{"key":"e_1_2_9_12_1","first-page":"620","article-title":"Quantitative assessment of platelet morphology by light scattering: a potential method for the evaluation of platelets for transfusion","volume":"103","author":"Fratantoni JCP","year":"1984","journal-title":"J Lab Clin Med"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1423-0410.2011.01468.x","article-title":"In vitro storage characteristics of platelet concentrates suspended in 70% SSP+ TM additive solution versus plasma over a 14\u2010day storage period","volume":"101","author":"Saunders C","year":"2011","journal-title":"Vox Sang"},{"key":"e_1_2_9_14_1","unstructured":"Kabi F.CompoStop\u2122 flex\u2014product folder. 2020. Available from:https:\/\/www.fresenius\u2010kabi.com\/content\/dam\/fresenius\u2010kabi\/no\/products\/product\u2010documents\/compostop\u2010flex\/CompoStop%20flex_BioP%20flex%2005%20\u2010%20Product%20Folder.pdf.coredownload.inline.pdf. Bad Homburg Germany. Last accessed 16 Mar 2026."},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2141.1998.00990.x","article-title":"Bioactive substances in buffy\u2010coat\u2010derived platelet pools stored in platelet\u2010additive solutions","volume":"103","author":"Edvardsen L","year":"1998","journal-title":"Br J Haematol"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ajh.1099","article-title":"Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates","volume":"67","author":"Edvardsen L","year":"2001","journal-title":"Am J Hematol"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/trf.12834","article-title":"Metabolomic analysis of platelets during storage: a comparison between apheresis\u2010 and buffy coat\u2010derived platelet concentrates","volume":"55","author":"Paglia G","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/trf.14974","article-title":"Soluble CD40L and CD62P levels differ in single\u2010donor apheresis platelet concentrates and buffy coat\u2013derived pooled platelet concentrates","volume":"59","author":"Sut C","year":"2019","journal-title":"Transfusion"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter SJ","year":"2010","journal-title":"N Engl J Med"},{"key":"e_1_2_9_20_1","article-title":"Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation","volume":"2015","author":"Estcourt LJ","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/17511437231206013","article-title":"Prophylactic platelet transfusions in critical care: how low can you go?","volume":"25","author":"Shah A","year":"2024","journal-title":"J Intensive Care Soc"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.21037\/aob-24-21","article-title":"A dose of platelets: getting it just right","volume":"9","author":"Friedman MT","year":"2024","journal-title":"Ann Blood"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/vox.12051","article-title":"Evaluation of the quality of blood components prepared using the Reveos automated blood processing system","volume":"105","author":"Johnson L","year":"2013","journal-title":"Vox Sang"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103195","article-title":"Remodelling whole blood processing through automation and pathogen reduction technology at the Luxembourg Red Cross","volume":"60","author":"Malvaux N","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/trf.15036","article-title":"The argument(s) for lowering the US minimum required content of apheresis platelet components","volume":"59","author":"Benjamin RJ","year":"2019","journal-title":"Transfusion"},{"key":"e_1_2_9_26_1","unstructured":"Lifeblood ARC.Platelets. Available from:https:\/\/www.lifeblood.com.au\/health-professionals\/products\/blood-components\/platelets. Last accessed 6 Jun 2026."},{"key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/09537104.2021.1961711","article-title":"Current challenges in platelet transfusion","volume":"33","author":"Smethurst P","year":"2022","journal-title":"Platelets"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/trf.16723","article-title":"Evaluating apheresis platelets at reduced dose as a contingency measure for extreme shortages","volume":"62","author":"Smethurst PA","year":"2022","journal-title":"Transfusion"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70387","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.70387","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:25:11Z","timestamp":1791851111000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":27,"alternative-id":["10.1111\/vox.70387"],"URL":"https:\/\/doi.org\/10.1111\/vox.70387","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"article-number":"vox.70387"}}